Vivek Subbiah: Precision Oncology’s Harsh Reality
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“For your Sunday reading: Our JCO Global Oncology
American Society of Clinical Oncology (ASCO) journal paper reveals precision oncology’s harsh reality -life-saving personalized cancer treatments exist but remain out of reach for most patients globally due to policy failures & economic barriers. Time to bridge this gap. Lives depend on it.
Precision Oncology: A Global Perspective on Implementation and Policy Development.”
Title: Precision Oncology: A Global Perspective on Implementation and Policy Development
Authors: Denis Horgan, Marcel Tanner, Charu Aggarwal, David Thomas, Surbhi Grover, Lina Basel-Salmon, Rodrigo Dienstmann, Tira Jing Ying Tan, Woong-Yang Park, Hadi Mohamad Abu Rasheed, Lillian L. Siu, Brigette Ma, Rocío Ortiz-López, Marc Van den Bulcke, Silvia Castillo Taucher, Andrea Ferris, Naureen Starling, Umberto Malapelle, John Longshore, Hugo Alberto Barrera Saldaña, Vivek Subbiah
Read the Full Article on JCO Global Oncology.
More posts featuring Vivek Subbiah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023